The slump in healthcare listed stocks and downward valuations of private businesses are encouraging potential buyers to examine enticing European healthcare enterprises.
Saudi Arabia’s health ministry is making $13bn (SR48bn) plans for 100 healthcare projects that will involve the private sector. The public-private partnership proposals include constructing two new medical cities, a project to provide 900 beds for medical rehabilitation, and long-term care services, and it looks like foreign investors are actively being courted.
French labs are presenting a united front pushing back against the €250m worth of annual cuts proposed in the 2023 Social Security Budget. All of the sector’s representative bodies have voiced outrage, and a joint letter from the directors of four labs syndicates sent to l’Assurance Maladie’s (CNAM) general director demands tariffs be indexed to inflation saying the sector cannot support further cuts.
The French government is to increase allocated funding for the health and care sectors overall in 2023, including hiring an additional 3,000 carers and investing €370m into a shift to care at home, but decrease funding for labs by €250m, as detailed in the 2023 Social Security budget, published on Monday September 26.
Last month we reported that there is a growth opportunity for bigger and more efficient for-profits in the largely unconsolidated Dutch labs market, as Covid testing winds down and financial pressures return to the sector. But a consultant who has previously run a Dutch hospital lab tells us a major barrier remains: a stubborn reluctance within hospitals to outsource.
The French statutory insurer is reported to be seeking tariff cuts for the labs sector which could exceed €200m. Any cuts will be announced on Monday, September 26, in the government’s Social Security Budget.
The fast growing for-profit healthcare market in Hungary is scaling new peaks. HBI hears it could be worth as much as HUF 450-500bn (in excess of €1bn), and talks to a local operator to find out more about why revenue growth is not always translating into profit.
Giuseppe Recchi is stepping down as CEO of Affidea, Europe’s largest imaging company. The new CEO will continue the company’s ambition to expand into more European markets.
Opportunities for consolidation in the German diagnostic labs sector have almost dried up, according to a large lab operator. But the market as a whole will continue to grow strongly post-Covid, with revenue up as much as 4-5% per annum, he said.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
